← Back to patent-cliff list
Sumifilam
Tier C — Watch / tradeSumifilam
Cassava Sciences Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FLN-A
Brand：FILORA
Indications (approved)：Alzheimer's disease, Hepatic function decline
Regional status
US
Phase III
2021-11-03
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sumifilam?
Approved indications include: Alzheimer's disease, Hepatic function decline.
When does the Sumifilam patent expire?
No public expiry year is available for Sumifilam yet; this page updates once verified.
How do I get a quote for Sumifilam intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06